Since the last CCSG renewal, Development Funds have supported 1) the recruitment of ten outstanding early career investigators, 2) development of two new shared resources and implementation of eight new services in existing shared resources, and 3) partial funding for fourteen MD Anderson Multidisciplinary Research Program (MRP) awards. The $500,000 of CCSG support for faculty recruitment has leveraged over $5.0M in MD Anderson start-up packages and more than $29.6M in new extramural grants. MRP awards provide seed funding of $250,000 over 3 years for groups of three or more center members to support planning and development of P01, SPORE, and CPRIT multi-investigator grant applications. Since the inception of the program in 1997, MD Anderson has invested $11.2M in MRP grants. These awards have been associated with external peer-reviewed funding of more than $157M, representing a 14.1-fold return on investment. During the present grant cycle, 17 proposals have been supported with $625,000 from CCSG Development Funds matched approximately 5:1 with institutional funds. This investment of CCSG support has leveraged $18.6M in extramural funding to date, with $8.8M from Multi-PI awards and $9.8M from individual investigator awards that resulted from projects supported as part of an MRP. Development Funds supported establishing the Functional Genomics Core (FGC) and the Assessment, Intervention and Measurement (AIM) core. In the current CCSG application, Development Funds are requested to continue support for faculty recruitment and fund additional MRP awards. Support is also requested for four developing shared resources: the Oncology Research and Immuno-Monitoring Core (ORION), the Microbiome Core Facility, the Shared Decision Making (SDM) Core, and the Metabolomics Core. Development Funds to provide support for establishing new methods and implementing new technologies within the shared resources and to fund collaborative pilot projects within and between programs are also proposed.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-44
Application #
9997838
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Abbas, Hussein A; Bui, Ngoc Hoang Bao; Rajapakshe, Kimal et al. (2018) Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes. Cancer Res 78:451-462
Zhu, Lele; Xie, Xiaoping; Zhang, Lingyun et al. (2018) TBK-binding protein 1 regulates IL-15-induced autophagy and NKT cell survival. Nat Commun 9:2812
Viswanathan, Chitra; Faria, Silvana; Devine, Catherine et al. (2018) [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer. PET Clin 13:165-177
Debnam, James M; Chi, Tzehping L; Ketonen, Leena et al. (2018) Superiority of Multidetector Computed Tomography With 3-Dimensional Volume Rendering Over Plain Radiography in the Assessment of Spinal Surgical Instrumentation Complications in Patients With Cancer. J Comput Assist Tomogr :
Patel, V K; Lamothe, B; Ayres, M L et al. (2018) Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia 32:920-930
Ravandi, Farhad; Ritchie, Ellen K; Sayar, Hamid et al. (2018) Phase 3 results for vosaroxin/cytarabine in the subset of patients ?60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica 103:e514-e518
Assi, Rita; Kantarjian, Hagop M; Kadia, Tapan M et al. (2018) Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124:2758-2765
Yam, Clinton; Murthy, Rashmi K; Valero, Vicente et al. (2018) A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs 36:299-306
Lacourt, Tamara E; Vichaya, Elisabeth G; Escalante, Carmen et al. (2018) An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology 96:109-117
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420

Showing the most recent 10 out of 12418 publications